tarsus-logo-stacked-color-532x626.png
Tarsus Announces Positive Topline Data from Phase 1b Callisto Trial and Initiates Phase 2a Carpo Human Tick Kill Trial Evaluating TP-05, A Novel, Oral Therapeutic for the Prevention of Lyme Disease
December 15, 2022 08:30 ET | Tarsus Pharmaceuticals, Inc
Positive Phase 1b Callisto data shows that TP-05 is well tolerated and safety data supports progression to Phase 2a Phase 2a Carpo trial to evaluate the safety, tolerability, and proof-of-activity of...
tarsus-logo-stacked-color-532x626.png
Tarsus to Present Additional Saturn-2 Pivotal Phase 3 Trial Data at the American Academy of Optometry 2022 Annual Meeting
October 25, 2022 08:30 ET | Tarsus Pharmaceuticals, Inc
Saturn-2 follow-up data to be presented on TP-03 for the treatment of Demodex blepharitis Tarsus recently submitted NDA to the FDA for TP-03 Data from an investigator-initiated trial evaluating...
tarsus-logo-stacked-color-532x626.png
Tarsus Announces Transition Plans for Board of Directors
October 11, 2022 08:30 ET | Tarsus Pharmaceuticals, Inc
Co-founder and Chairman Michael Ackermann plans to transition off Board of Directors Wendy Yarno will become Lead Independent Director and CEO Bobak Azamian will become Chairman upon Dr. Ackermann’s...
tarsus-logo-stacked-color-532x626.png
Tarsus Appoints Scott Morrison as Board Member and Audit Committee Chair
October 06, 2022 08:30 ET | Tarsus Pharmaceuticals, Inc
Mr. Morrison brings over 40 years of financial and operational expertise in life sciences IRVINE, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose...
Look at the Lids Website
Tarsus Launches “Look at the Lids” Campaign to Encourage Eye Care Professionals to Identify and Diagnose Demodex Blepharitis
September 29, 2022 08:30 ET | Tarsus Pharmaceuticals, Inc
Demodex blepharitis is a highly prevalent, yet often missed or misdiagnosed lid margin disease that impacts approximately 25 million eye care patients in the U.S. IRVINE, Calif., Sept. 29, 2022 ...
tarsus-logo-stacked-color-532x626.png
Tarsus to Present Saturn-2 Pivotal Phase 3 Trial Data and Saturn-1 Extension Study Long-Term Safety Data Evaluating TP-03 for the Treatment of Demodex Blepharitis at Upcoming Eye Care Meetings
September 27, 2022 12:00 ET | Tarsus Pharmaceuticals, Inc
Positive data to be presented at WCC VIII and AAO 2022 conferences in Chicago Tarsus recently submitted NDA to the FDA for TP-03 IRVINE, Calif., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Tarsus...
tarsus-logo-stacked-color-532x626.png
Tarsus Initiates Phase 2a Ersa Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease
August 05, 2022 08:30 ET | Tarsus Pharmaceuticals, Inc
IRVINE, Calif., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
tarsus-logo-stacked-color-532x626.png
Tarsus Presents New Findings from Two Studies Demonstrating the Impact of Demodex Blepharitis at the ARVO 2022 Annual Meeting
May 05, 2022 08:30 ET | Tarsus Pharmaceuticals, Inc
IRVINE, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
tarsus-logo-stacked-color-532x626.png
Tarsus Presents Results of Two Studies Highlighting Demodex Blepharitis Patient Impact and Burden at the ASCRS 2022 Annual Meeting
April 26, 2022 08:30 ET | Tarsus Pharmaceuticals, Inc
IRVINE, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
tarsus-logo-stacked-color-532x626.png
Tarsus Expands Executive Leadership Team with the Appointment of José Trevejo, M.D., Ph.D., as Chief Medical Officer
February 03, 2022 09:00 ET | Tarsus Pharmaceuticals, Inc
Dr. Trevejo brings over 20 years of clinical development experience to Tarsus as it advances development of TP-03, the first potential treatment for Demodex blepharitis, and its pipeline programs ...